B-RAF is the most frequently mutated protein kinase in human cancers 1 . The finding that
oncogenic mutations in BRAF are common in melanoma 2 , followed by the demonstration …

The tuberous sclerosis complex (TSC), a multisystem, autosomal dominant disorder affecting
children and adults, results from mutations in one of two genes, TSC1 (encoding hamartin) …

Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1)
in human melanoma, most patients do not experience durable clinical benefit. Pre-existing …

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF
inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF …

Therapies that target signalling molecules that are mutated in cancers can often have
substantial short-term effects, but the emergence of resistant cancer cells is a major barrier to full …

Background: Increasing numbers of BRCA1 mutation carriers are being identified in cancer
risk evaluation programs. However, no estimates of cancer risk specific to a clinic-based …

Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Many cancer-associated genes remain to be identified to clarify the underlying molecular
mechanisms of cancer susceptibility and progression. Better understanding is also required of …

We report a comprehensive molecular characterization of pheochromocytomas and
paragangliomas (PCCs/PGLs), a rare tumor type. Multi-platform integration revealed that PCCs/…

Germline mutations in the tumour suppressor gene PTEN have been implicated in two
hamartoma syndromes that exhibit some clinical overlap, Cowden syndrome (CS) and Bannayan-…